An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...
Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025. Data from the KEYNOTE-905 trial (NCT03924895) showed that perioperative enfortumab vedotin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback